TruSight Oncology 500

Assay targeting multiple variant types, including tumor mutational burden (TMB) and microsatellite instability (MSI), even from low-quality samples. Read More...
Select Product(s)

TruSight Oncology 500 DNA Kit (48 samples)

20028213

Price
 
 

TruSight Oncology 500 DNA Kit, For Use with NextSeq (48 samples)

20028214

Price
 
 

TruSight Oncology 500 DNA/RNA Bundle, (16 indexes, 24 samples)

20028215

Price
 
 

TruSight Oncology 500 DNA/RNA Bundle, for use with NextSeq (16 indexes, 24 samples)

20028216

Price
 
 

Product Highlights

TruSight Oncology 500 is a next-generation sequencing (NGS) tumor profiling assay that analyzes hundreds of cancer-related biomarkers. It supports identification of all relevant DNA and RNA* variants implicated in various tumor types.

In addition, it accurately measures the key immunotherapy biomarkers: tumor mutation burden (TMB) and microsatellite instability (MSI).

Save Time, Money, and Samples through Test Consolidation

  • Pan-cancer content aligned with key guidelines
  • DNA + RNA* assay targeting 523 genes for assessment of small variants, TMB, MSI, splice variants, and fusions
  • Identify relevant alterations while achieving highly accurate results

Achieve Highly Confident Results

  • Software filters artifacts for accurate variant calling
  • Enrichment chemistry inclusive of unique molecular indexes (UMIs) for high sensitivity in variant detection
  • Based on proven Illumina platform

Unlock Immuno-Oncology

  • Panel contains immuno-oncology biomarkers TMB and MSI
  • Tumor-only workflow for simplicity and efficiency
  • TMB calling performance similar to whole-exome sequencing (WES) panels
  • Large 1.94 Mb panel and sophisticated algorithm for accurate TMB score

* The products to evaluate DNA and RNA variants consist of the TruSight Oncology 500 DNA panel and the TruSight Tumor 170 RNA panel

Frequently Purchased Together

Specifications

Method-Specific Workflow Example

 

Supporting Data and Figures

 

Related Products

TruSight Tumor 170

Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample.


TruSight Oncology

TruSight Oncology is a set of NGS platform reagents for the detection of cancer variants, using an enrichment-based method to simultaneously analyze DNA and RNA. Gene content is not included.


TruSight RNA Fusion Panel

Provides comprehensive gene fusion detection in formalin-fixed, paraffin-embedded (FFPE) and other cancer research samples.